A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee
Public ClinicalTrials.gov record NCT01147458. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blinded, Double-Dummy, Placebo And Active Controlled Two Cohort Two-Way Cross-Over, Multi-Centre Clinical Trial To Examine The Pain Relief Produced By 2 Weeks Of Daily Oral Administration Of A 5-Lipoxygenase (5-Lox) Inhibitor PF-04191834 Alone And In Combination With Naproxen In Patients With Flare-Enriched Osteoarthritis Of The Knee
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or with naproxen, particularly to test if patients have less pain.
Study identification
- NCT ID
- NCT01147458
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 190 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- Feb 2011 (Actual)
- Completion
- Feb 2011 (Actual)
- Last update posted
- Jun 6, 2013
2010 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Peoria | Arizona | 85381 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85013 | — |
| Pfizer Investigational Site | Phoenix | Arizona | 85015 | — |
| Pfizer Investigational Site | Anaheim | California | 92801 | — |
| Pfizer Investigational Site | Carmichael | California | 95608 | — |
| Pfizer Investigational Site | Fair Oaks | California | 95628 | — |
| Pfizer Investigational Site | San Diego | California | 92128 | — |
| Pfizer Investigational Site | Denver | Colorado | 80209 | — |
| Pfizer Investigational Site | DeLand | Florida | 32720 | — |
| Pfizer Investigational Site | Pensacola | Florida | 32504 | — |
| Pfizer Investigational Site | South Miami | Florida | 33143 | — |
| Pfizer Investigational Site | South Bend | Indiana | 46601 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66211 | — |
| Pfizer Investigational Site | Overland Park | Kansas | 66212 | — |
| Pfizer Investigational Site | Worcester | Massachusetts | 01610 | — |
| Pfizer Investigational Site | Edina | Minnesota | 55435 | — |
| Pfizer Investigational Site | Saint Paul | Minnesota | 55114 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89144 | — |
| Pfizer Investigational Site | Monroe | North Carolina | 28112 | — |
| Pfizer Investigational Site | Fargo | North Dakota | 58103 | — |
| Pfizer Investigational Site | Columbus | Ohio | 43213 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19139 | — |
| Pfizer Investigational Site | Austin | Texas | 78705 | — |
| Pfizer Investigational Site | Arlington | Virginia | 22205 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01147458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 6, 2013 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01147458 live on ClinicalTrials.gov.